Publication
Published on: October 22, 2022
Published in: Contemporary Clinical Trials

Published on: December 7, 2022
Published in: Journal of Empirical Research on Human Research Ethics
Published recently in the Journal of Empirical Research on Human Research Ethics, Luke Gelinas, David Strauss, Hayat Ahmed, Barbara Bierer, and others co-authored an article entitled, “Protecting the Vulnerable and Including the Under-Represented: IRB Practices and Attitudes.” A pilot national survey of IRB Chairs was conducted to assess attitudes and practices with regard to protecting the vulnerable and including under-represented groups in research.
Presented on: November 29 & 30, 2022
Presented at: Advancing International Pediatric Clinical Research webinar series: Facilitating Pediatric Medicines Development: Models of Global Cooperation
See related webinars, maintained on our website:
Informing the Future from COVID-19 Lessons Learned
Time To Listen: Hearing From Young People in Clinical Research
Assent and consent in the field: culture, context, and respect
Developed on: August 2020
Developed by: MRCT Center Diversity Workgroup
See related Resources, maintained on our project specific website:
Diversity, Inclusion, and Equity in Clinical Research
Participant and Community Engagement
Participant Awareness, Knowledge, and Access
Released on: April 6, 2017
Published in: Journal of Medical Ethics
Ensuring that clinical trials, once launched, successfully complete and generate useful knowledge is an important and indeed ethically imperative goal, given the risks and burdens borne by research participants. Since there are insufficient willing research participants to power all the trials that are currently undertaken,1 addressing underenrolment will require prioritisation decisions that reduce the number of trials competing for participants. While there are multiple levels at which research priority-setting can and does take place, competition between trials often plays out in real time at the institutional or site level, where complex decisions must be made about how to manage overlapping trials in ways that balance different considerations, including the risk of non-completion. We sought to explore what research institutions in particular might ethically do to mitigate the risk that competition between trials will contribute to recruitment shortfalls.
Published on: December 7, 2016
Developed by: Vivli and MRCT Center Data Sharing and Transparency Workgroups
Released on: June 14, 2022
Published in: BIO International Convention, San Diego CA
Dr. Willyanne DeCormier Plosky, Program Manager at the MRCT Center, presented on this panel, which explored emerging principles and concrete strategies for addressing demographic disparities and achieving representativeness in clinical trials. The panel was organized and moderated by Lindsay Cobbs (BeiGene USA Inc.), and also included Melika Davis (BeiGene USA Inc.), Jacqueline Corrigan-Curay (FDA); Meg Alexander (Ovid Therapeutics Inc.), and Tesheia Johnson (Yale University) as speakers. See the recording here.